Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Bullboard Posts
Comment by ANALIAS00on May 01, 2018 5:01pm
110 Views
Post# 27966779

RE:RE:RE:RE:Thousands of bottles

RE:RE:RE:RE:Thousands of bottles
jfm1330 wrote: Management already said in the last CC that they were contacted by clinics to be provided with forms to do prescriptions. I am sure this has just grown since then. Also, I think that in the beginning a good part of the patients will not come through sales reps, but just from the need for the drug and by requests from well informed patients and doctors. Sales reps biggest effect will be to bring in those who are not already well aware of Trogarzo and its benefits.

What I will be interested in is the number of patients on the drug. I think the company said they don't want to disclose it, but this is the key element. Money will follow.


Maybe they will eventually tells us the amount of patient on the drug.  But if they dont, what could be the reason for not providing it ?     Are there any kind of public institution that would require that info from TH or from other mecanism for statistics or other useful purposes ?

Bullboard Posts